Study of ALN-CIDEB for liver fat disease
Part of Digestive system, Hormones & metabolism clinical trials.
This trial tests a new treatment called ALN-CIDEB for adults with a liver condition called MASLD, where fat builds up in the liver. The treatment aims to reduce liver fat and improve liver health.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with MASLD (fatty liver disease).
- A special scan showed your liver is moderately stiff (between 6 and 20 on the scan), meaning you have some liver damage but not too advanced.
- You do not have other chronic liver diseases like hepatitis.
- You have not had liver transplant surgery and are not on a transplant waiting list.
- You have not had alcohol or drug abuse in the past year.
- You are not taking certain diabetes or weight-loss drugs (like GLP-1s) or MASH medications, or you have been on the same dose for at least 3 months without changes.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug called ALN-CIDEB for people with fatty liver disease (MASLD or MASH). The goal is to see if it can reduce liver fat and improve liver health. You may qualify if you have a higher BMI and evidence of liver fat on imaging tests.
This study is testing whether advanced imaging and other non-invasive methods can properly identify people with significant liver scarring due to metabolic liver disease or alcohol-related liver disease. It may help find better ways to track liver health without repeated needle biopsies.
This trial tests new medicines for adults with fatty liver disease (MASLD) that has already caused some liver scarring. It aims to see if these drugs can help prevent the liver disease from getting worse.
This study looks at a new non-invasive screening method to predict metabolic dysfunction–associated steatotic liver disease (MASLD), a condition where fat builds up in the liver. The goal is to help identify people who may be at risk without needing invasive tests.
This study tests whether adding a liver stiffness measurement to a lifestyle program helps people with MASLD (a type of fatty liver disease) improve their liver health. It is designed for people who have fatty liver and at least one sign of metabolic syndrome, like high blood pressure or diabetes.
This study tests a new device called LiverScope® that scans your liver to detect fatty liver disease (MASLD). The scan uses special imaging technology and may help doctors diagnose liver disease more quickly and accurately.
Hear when a new Metabolic Dysfunction-Associated Steatotic Liver Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.